Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enanta Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Tickers ENTA
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.